Inhibrx reports Q1 results; Sanofi merger with $30/shr cash, CVR, and spin-off set for May 30

Inhibrx, Inc.

Sanofi to acquire INBRX-101 assets; shareholders receive $30/shr cash + $5 CVR + 1/4 share of New Inhibrx.
Merger closing and spin-off expected May 30; special meeting May 24; when-issued trading of New Inhibrx (INXB) starts May 16.
Q1 net loss $78.7M ($1.44/shr) vs $48.9M ($1.12/shr) YoY; R&D expense up 71% to $63.9M.
Cash $252.5M at Mar 31, down from $277.9M at Dec 31; $38.7M in stock option proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inhibrx, Inc. reported the first quarter of 2024 results: net income $78.7 million, EPS $1.44 per share.

Period: the first quarter of 2024
Net income: $78.7 million
EPS: $1.44 per share
Result: reported results

Exact text from the filing

Net loss was $78.7 million during the first quarter of 2024, or $1.44 per share, compared to $48.9 million during the first quarter of 2023, or $1.12 per share.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001739614-24-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.